Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Net Cash used for Investing Activities?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Net Cash used for Investing Activities is 
$1.7B (1Y +62.5% )

ALXN Stock Price & Net Cash used for Investing Activities

Net Cash used for Investing Activities for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Net Cash used for Investing Activities

chevron_right 2021 $80.6M +805x
( +28.1% / year avg)
chevron_left 1995 $100.0K
vertical_align_top Peak $3.5B +17.2x *
vertical_align_bottom Bottom -$215.0M
arrow_drop_up # Up Years 12 12 of 27
years up.
arrow_drop_down # Down Years 15
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or +0.06x the rate relative to it's net cash used for investing activities over the same period.
  • If ALXN grows it's stock at the same rate as it's net cash used for investing activities (+28.1%/year) , it's stock price will grow +1,189% and hit $1293.6 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 12 years (0%) it's net cash used for investing activities were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Net Cash used for Investing Activities Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Net Cash used for Investing Activities YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $80 -95.9% - -
    4/1/2020 $1,962 -1013.0% - -
    4/1/2019 $-214 4.6% - -
    4/1/2018 $-205 -125.5% - -
    4/1/2017 $804 61.6% - -
    4/1/2016 $497 -85.7% - -
    4/1/2015 $3,485 304.4% - -
    4/1/2014 $861 67.1% - -
    4/1/2013 $515 -44.0% - -
    4/1/2012 $920 1975.9% - -
    4/1/2011 $44 -58.6% - -
    4/1/2010 $107 50.1% - -
    4/1/2009 $71 545.3% - -
    4/1/2008 $11 -642.3% - -
    4/1/2007 $-2 -95.3% - -
    4/1/2006 $-43 -15.5% - -
    4/1/2005 $-51 117.1% - -
    4/1/2004 $-23 -27.0% - -
    4/1/2003 $-32 -186.0% - -
    4/1/2002 $37 -66.9% - -
    4/1/2001 $113 -0.2% - -
    4/1/2000 $114 1770.4% - -
    4/1/1999 $6 577.8% - -
    4/1/1998 $0 -147.4% - -
    4/1/1997 $-1 -121.1% - -
    4/1/1996 $9 8900.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Cash flows from investing activities provides an account of cash used in the purchase of non-current assets–or long-term assets– that will deliver value in the future.

    For more detailed definitions, please see Investopedia.